Epidemiologic and clinic studies have revealed that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of colorectal cancer, acting primarily through inhibiting cyclooxygenase-1 (COX-1) and COX-2, two enzymes involved in prostaglandin biosynthesis. Here, PTGS1 is linked to colorectal cancer.